WallStreetZenWallStreetZen

NASDAQ: IART
Integra Lifesciences Holdings Corp Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for IART

Based on 6 analysts offering 12 month price targets for Integra Lifesciences Holdings Corp.
Min Forecast
$56.00+32.45%
Avg Forecast
$68.00+60.83%
Max Forecast
$87.00+105.77%

Should I buy or sell IART stock?

Based on 6 analysts offering ratings for Integra Lifesciences Holdings Corp.
Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 16.67%
Hold
4 analysts 66.67%
Sell
1 analysts 16.67%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IART stock forecasts and price targets.

IART stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Morgan Stanley
Bottom 20%
20
HoldMaintains$58.00+37.18%2022-08-25
Truist Securities
Top 8%
93
HoldMaintains$56.00+32.45%2022-07-20
Citigroup
Top 8%
93
HoldMaintains$67.00+58.47%2022-05-17
Bank of America
Top 1%
100
SellMaintains$65.00+53.74%2022-01-18
JP Morgan
Bottom 40%
40
HoldUpgrades$75.00+77.39%2021-12-17
Credit Suisse
Bottom 6%
6
BuyMaintains$87.00+105.77%2021-11-03

1 of 1

Forecast return on equity

Is IART forecast to generate an efficient return?
Company
21.07%
Industry
24.3%
Market
119.16%
IART's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IART forecast to generate an efficient return on assets?
Company
9.32%
Industry
13.21%
IART is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IART earnings per share forecast

What is IART's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$3.14+58.59%
Avg 2 year Forecast
$3.51+77.27%
Avg 3 year Forecast
$3.78+90.91%
IART's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

IART revenue forecast

What is IART's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$1.6B-0.34%
Avg 2 year Forecast
$1.6B+4.06%
Avg 3 year Forecast
$1.7B+9.12%
IART's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IART earnings growth forecast

How is IART forecast to perform vs Medical Devices companies and vs the US market?
Company
24.05%
Industry
19.73%
Market
16.69%
IART's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
IART's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
IART's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

IART revenue growth forecast

How is IART forecast to perform vs Medical Devices companies and vs the US market?
Company
2.95%
Industry
4.81%
Market
8.53%
IART's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IART's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IART vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
IART$42.28$68.00+60.83%Hold
NARI$69.25$94.83+36.94%Strong Buy
AXNX$68.51$77.86+13.64%Strong Buy
TNDM$46.53$90.17+93.78%Buy
LIVN$50.01$90.20+80.36%Strong Buy
View Top Medical Device Stocks

Integra Lifesciences Holdings Stock Forecast FAQ

Is Integra Lifesciences Holdings Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: IART) stock is to Hold IART stock.

Out of 6 analysts, 0 (0%) are recommending IART as a Strong Buy, 1 (16.67%) are recommending IART as a Buy, 4 (66.67%) are recommending IART as a Hold, 1 (16.67%) are recommending IART as a Sell, and 0 (0%) are recommending IART as a Strong Sell.

If you're new to stock investing, here's how to buy Integra Lifesciences Holdings stock.

What is IART's earnings growth forecast for 2022-2024?

(NASDAQ: IART) Integra Lifesciences Holdings's forecast annual earnings growth rate of 24.05% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 19.73%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.69%.

Integra Lifesciences Holdings's earnings in 2022 is $166,302,000.On average, 3 Wall Street analysts forecast IART's earnings for 2022 to be $262,204,036, with the lowest IART earnings forecast at $261,368,991, and the highest IART earnings forecast at $263,874,125. On average, 8 Wall Street analysts forecast IART's earnings for 2023 to be $293,100,690, with the lowest IART earnings forecast at $276,399,796, and the highest IART earnings forecast at $303,121,226.

In 2024, IART is forecast to generate $315,646,897 in earnings, with the lowest earnings forecast at $307,296,450 and the highest earnings forecast at $323,997,344.

What is IART's revenue growth forecast for 2022-2024?

(NASDAQ: IART) Integra Lifesciences Holdings's forecast annual revenue growth rate of 2.95% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Integra Lifesciences Holdings's revenue in 2022 is $1,566,838,000.On average, 3 Wall Street analysts forecast IART's revenue for 2022 to be $130,391,645,374, with the lowest IART revenue forecast at $129,790,997,721, and the highest IART revenue forecast at $131,462,757,210. On average, 7 Wall Street analysts forecast IART's revenue for 2023 to be $136,149,445,589, with the lowest IART revenue forecast at $134,406,289,778, and the highest IART revenue forecast at $140,205,675,219.

In 2024, IART is forecast to generate $142,772,519,123 in revenue, with the lowest revenue forecast at $139,608,451,250 and the highest revenue forecast at $146,999,598,899.

What is IART's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: IART) forecast ROA is 9.32%, which is lower than the forecast US Medical Devices industry average of 13.21%.

What is IART's Price Target?

According to 6 Wall Street analysts that have issued a 1 year IART price target, the average IART price target is $68.00, with the highest IART stock price forecast at $87.00 and the lowest IART stock price forecast at $56.00.

On average, Wall Street analysts predict that Integra Lifesciences Holdings's share price could reach $68.00 by Aug 25, 2023. The average Integra Lifesciences Holdings stock price prediction forecasts a potential upside of 60.83% from the current IART share price of $42.28.

What is IART's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: IART) Integra Lifesciences Holdings's current Earnings Per Share (EPS) is $1.98. On average, analysts forecast that IART's EPS will be $3.14 for 2022, with the lowest EPS forecast at $3.13, and the highest EPS forecast at $3.16. On average, analysts forecast that IART's EPS will be $3.51 for 2023, with the lowest EPS forecast at $3.31, and the highest EPS forecast at $3.63. In 2024, IART's EPS is forecast to hit $3.78 (min: $3.68, max: $3.88).

What is IART's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: IART) forecast ROE is 21.07%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.